Gene: PROC ×
Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 GeneticVariation phenotype LHGDN Factor V Leiden, prothrombin G20210A, and protein C mutation frequency in Turkish venous thrombosis patients. 18160601 2008
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 Biomarker phenotype CTD_human Severe congenital protein C deficiency: description of a new mutation and prophylactic protein C therapy and in vivo pharmacokinetics. 18376272 2008
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 Biomarker phenotype LHGDN In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. 16105054 2005
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 GeneticVariation phenotype LHGDN These data indicate that individuals carrying the 4600AG genotype have high sEPCR levels but do not have an increased risk of thrombosis, whereas individuals carrying the 4678CC genotype have higher APC levels and lower risk of venous thromboembolism. 15116250 2004
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 GeneticVariation phenotype LHGDN The data from this model predict an increased risk of perioperative thrombosis due to inhibition of APC function in cardiac surgical patients heterozygous for the F5L mutation. 11761087 2001
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 Biomarker phenotype CTD_human Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127-->a mutation in the thrombomodulin gene. 11132655 2000
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 Biomarker phenotype CTD_human Lipoprotein (a): its role in childhood thromboembolism. 9164807 1997
Entrez Id: 5624
Gene Symbol: PROC
PROC 		0.340 Biomarker phenotype CTD_human Even in these risk groups, the cost-benefit ratio of selective screening is unfavorable, as today at most 70% of the hereditary thrombophilias can be diagnosed by laboratory analysis, and only very few of the patients will actually experience a thrombotic event: only 3 of 1000 carriers of APC-resistance will suffer from thrombosis during oral contraception. 8967151 1996